Literature DB >> 34185142

Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region.

Hidetaka Uramoto1, Tomoya Takiguchi2, Tomonobu Koizumi3, Azusa Tanimoto4, Ryuji Hayashi5, Yozo Nakazawa6, Ken-Ichi Ito7, Mitsutoshi Nakada8, Yasuo Hirono9, Yoshikazu Nishino2, Seiji Yano4.   

Abstract

BACKGROUND: Malignant pleural mesothelioma (MPM) is a major occupational and environmental neoplasm. The purpose of this study was to validate the clinical and epidemiological factors, diagnosis, and initial treatment among MPM patients in the Hokushin region.
METHODS: We surveyed retrospective data from 152,921 cancer patients in 22 principal hospitals.
RESULTS: A total of 166 MPM cases were newly diagnosed. These patients consisted of 136 men and 30 women, with a median age of 69 years. We estimated the incidence rate for MPM to be 0.55 cases per 100,000 person-years in this study. The ratio per 100,000 population-years was 0.39 in Fukui, 0.60 in Ishikawa, 1.02 in Toyama and 0.35 in Nagano. Forty-five patients were discovered when diagnosed incidentally in patients under observations for other diseases. Forty-six cases were diagnosed as localized disease, while 13 had accompanying regional lymph node metastasis. Furthermore, 44 cases showed infiltration into adjacent organs. A histo-cytological diagnosis was made in 164 cases (98.8%). A surgical approach, chemotherapy, and radiotherapy were performed for 33, 88, and 6 patients, respectively, while 44 patients (26.5%) received best supportive care. Multimodality therapy was conducted in just 3.0% of the MPM patients
CONCLUSION: MPM has a tragically rapid progression if discovered under observations for other diseases. Workers in health-related fields should be on high alert for aggressive MPM. Better evaluation and multi-disciplinary approaches to MPM in these regions are needed to optimize multimodality therapy.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cancer registration; Cancer screening; Ganpro database; Hokushin region; Malignant pleural mesothelioma

Mesh:

Year:  2021        PMID: 34185142     DOI: 10.1007/s00432-021-03699-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  21 in total

1.  National survey of malignant mesothelioma and asbestos exposure in Japan.

Authors:  Kenichi Gemba; Nobukazu Fujimoto; Katsuya Kato; Keisuke Aoe; Yukio Takeshima; Kouki Inai; Takumi Kishimoto
Journal:  Cancer Sci       Date:  2012-01-09       Impact factor: 6.716

2.  A historical cohort mortality study of workers exposed to asbestos in a refitting shipyard.

Authors:  N Kurumatani; Y Natori; R Mizutani; S Kumagai; M Haruta; H Miura; K Yonemasu
Journal:  Ind Health       Date:  1999-01       Impact factor: 2.179

3.  Clinical study on mesothelioma in Japan: Relevance to occupational asbestos exposure.

Authors:  Takumi Kishimoto; Kenichi Gemba; Nobukazu Fujimoto; Keisuke Aoe; Katsuya Kato; Yukio Takeshima; Kohki Inai
Journal:  Am J Ind Med       Date:  2010-11       Impact factor: 2.214

4.  Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.

Authors:  B C John Cho; Laura Donahoe; Penelope A Bradbury; Natasha Leighl; Shaf Keshavjee; Andrew Hope; Prodipto Pal; Michael Cabanero; Kasia Czarnecka; Karen McRae; Ming-Sound Tsao; Marc de Perrot
Journal:  Lancet Oncol       Date:  2021-01-12       Impact factor: 41.316

5.  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Paul Baas; Arnaud Scherpereel; Anna K Nowak; Nobukazu Fujimoto; Solange Peters; Anne S Tsao; Aaron S Mansfield; Sanjay Popat; Thierry Jahan; Scott Antonia; Youssef Oulkhouir; Yolanda Bautista; Robin Cornelissen; Laurent Greillier; Francesco Grossi; Dariusz Kowalski; Jerónimo Rodríguez-Cid; Praveen Aanur; Abderrahim Oukessou; Christine Baudelet; Gérard Zalcman
Journal:  Lancet       Date:  2021-01-21       Impact factor: 79.321

6.  Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.

Authors:  P Beckett; J Edwards; D Fennell; R Hubbard; I Woolhouse; M D Peake
Journal:  Lung Cancer       Date:  2015-03-30       Impact factor: 5.705

7.  Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008.

Authors:  S Jane Henley; Theodore C Larson; Manxia Wu; Vinicius C S Antao; Mary Lewis; Germania A Pinheiro; Christie Eheman
Journal:  Int J Occup Environ Health       Date:  2013 Jan-Mar

Review 8.  Malignant mesothelioma: current status and perspective in Japan and the world.

Authors:  Seiki Hasegawa; Fumihiro Tanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-07-08

Review 9.  Latent period for malignant mesothelioma of occupational origin.

Authors:  B P Lanphear; C R Buncher
Journal:  J Occup Med       Date:  1992-07

10.  Global mesothelioma epidemic: Trend and features.

Authors:  Claudio Bianchi; Tommaso Bianchi
Journal:  Indian J Occup Environ Med       Date:  2014-05
View more
  1 in total

1.  Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region.

Authors:  Hidetaka Uramoto; Tomoya Takiguchi; Tomonobu Koizumi; Azusa Tanimoto; Ryuji Hayashi; Yozo Nakazawa; Ken-Ichi Ito; Mitsutoshi Nakada; Yasuo Hirono; Yoshikazu Nishino; Seiji Yano
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-29       Impact factor: 4.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.